Rivaroxaban 10mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic disease by Stöllberger, Claudia & Finsterer, Josef
Case report
Rivaroxaban 10 mg/d in severe renal failure does
not prevent ischemic events in premorbid
neurologic disease
Claudia Stöllberger *, Josef Finsterer
Krankenanstalt Rudolfstiftung, Wien, Austria
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 8 0 – 1 8 2
a r t i c l e i n f o
Article history:
Received 23 March 2015
Accepted 11 April 2015
Available online 22 April 2015
Keywords:
Stroke
Anticoagulation
Atrial ﬁbrillation
Octogenarian
a b s t r a c t
Backgrund: The direct oral anticoagulants (DOAC) are increasingly used for primary and
secondary stroke prophylaxis in atrial ﬁbrillation, although their use in patients with renal
failure is problematic.
Case report: In an 82-years old female with recurrent strokes and atrial ﬁbrillation, the
vitamin-K-antagonist was changed to rivaroxaban because of ‘‘unstable international
normalized ratio (INR) values’’. Because of renal failure with a creatinine clearance of
32 ml/min, a dosage of rivaroxaban 10 mg/d was chosen. Eleven days after initiation of
rivaroxaban, she was re-hospitalized because of acute onset of right-sided weakness of the
upper and lower limbs.
Conclusions: In cases of stroke, renal failure and inadequate anticoagulation it is not useful to
change from vitamin-K-antagonists to ‘‘low dose’’ DOAC. Diligent investigations for the
cause of INR-instability and continuation of vitamin-K-antagonist therapy seem to be more
effective and safer since there is the opportunity of monitoring therapy and to avoid under-
as well as over-dosage.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Stroke prevention in atrial ﬁbrillation (AF) by the direct oral
anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban
was investigated in patients with no or only moderate renal
failure [1–3]. Renal failure is frequent in AF-patients [4–6].
All DOAC are eliminated at least partly by the kidneys,
and dose reduction is recommended for patients with a* Corresponding author at: Krankenanstalt Rudolfstiftung, Juchgasse 2
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renal impairment, deﬁned by a creatinine clearance <30 ml/
min were excluded from the rivaroxaban-investigating trials
[3]. Limited clinical data for patients with severe renal
impairment (creatinine clearance 15–29 ml/min) indicate that
rivaroxaban plasma concentrations are signiﬁcantly in-
creased. It is unknown if further dose reductions in more
severe renal failure will be efﬁcient and safe. We observed a
patient with AF and recurrent ischemic strokes, the last
occurring under ‘‘low dose’’ rivaroxaban.5, Steingasse 31/18, A-1030 Wien, Austria. Tel.: +43 676 403 11 87;
gs1@yahoo.de (J. Finsterer).
p. z o.o. All rights reserved.
Table 1 – Results of blood tests (Day 1 is the day on which she was re-hospitalized with the recurrent stroke).
Time of blood sampling Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Parameter (reference)
BUN, mg/dl (9–20) 37 26 34 35 36 32
Creatinine, mg/dl (<1.0) 1.64 1.17 1.51 1.3 1.39 1.26
Crea Cl, ml/min(>90)a 22 31 24 28 26 29
GFR, ml/min/1.73 (>90)b 30 44 33 39 36 41
Hemoglobin, g/dl (12–16) 13 NM 13.5 NM NM NM
Thrombocytes, nl1 (150–400) 217 NM 204 NM NM NM
INR 2.0 1.5 1.51 1.44 1.30 1.43
PT, % (70–130)c 34 NM 45 NM NM NM
aPTT, s (<33)d 39 NM 34.6 NM NM NM
Fibrinogen, g/l (1.5–4.5) NM NM 3.50 NM NM NM
NM = not measured.
a Crea Cl = creatinine clearance estimated according to the Cockcroft–Gault formula.
b GFR = glomerular ﬁltration rate estimated according to the modiﬁcation of diet in renal disease formula.
c PT = prothrombin time.
d aPTT = activated partial thromboplastin time.
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An 82-years old Caucasian female, 53 kg weight, with arterial
hypertension, diabetes mellitus, renal insufﬁciency and
hyperlipidemia underwent pulmonary-vein isolation in June
2013 because of paroxysmal AF. In the following weeks AF
recurred. In October 2013, she was hospitalized because of a
left-cerebral occipital ischemic stroke and 3 non-recent
ischemic lesions right frontal, occipital and parietal. Carotid
duplex-sonography showed bilateral arteriosclerotic plaques
without stenosis. Transthoracic echocardiography did not
show any cardiac thrombi or valvular abnormalities. Because
the international normalized ratio (INR) was 1.7, the stroke
was assumed by admitting physicians as due to ‘‘non-
adjustable INR’’, although the patient's records showed that
in the previous months her INR values were constantly 2.0–3.0.
The vitamin-K-antagonist-therapy with phenprocoumon was
changed to rivaroxaban. Because of renal failure with a
creatinine clearance of 32 ml/min a dosage of rivaroxaban
10 mg/d was given. She was discharged with a medication
comprising molsidomin, candesartan, amlodipine, spirono-
lactone and hydrochlorothiazide.
Eleven days after initiation of rivaroxaban she was re-
hospitalized because of acute onset of right-sided weakness of
the upper and lower limbs. Blood tests showed severe renal
failure (Table 1). Clinical neurologic investigation showed a
mild right-sided facial and hypoglossus palsy, mild right-sided
hemiparesis, and right-sided hypotonia and cerebral-magnet-
ic-resonance-imaging an ischemic left-sided thalamic lesion.
She was discharged with candesartan, amlodipine, escitalo-
pram, linagliptine, simvastatin, trazodone and, despite per-
sisting renal insufﬁciency, rivaroxaban 15 mg/d.
3. Discussion
This case reports about a fallacy leading to a dilemma resulting
in recurrent stroke. The fallacy: DOAC were initiated because
of ‘‘non-adjustable INR’’. Instable INR values may be due to
several reasons like impaired cognition, depressed mood, or
inadequate health literacy [7]. Instead of investigating thereason for the low INR-value which had presumably contrib-
uted to the stroke, the treating physicians changed from
vitamin-K-antagonists to DOAC without clarifying and solving
the underlying problem.
The dilemma: Rivaroxaban 10 mg/d was chosen because of
renal insufﬁciency. The dose chosen was not based on any
clinical trial data. Although the blood tests indicated that the
coagulation system was inﬂuenced by rivaroxaban, the
recurrent stroke indicates that the anticoagulant therapy
was not effective. A higher dose, however, might increase the
bleeding risk. Patients with a creatinine-clearance <30 ml/min
were excluded from the rivaroxaban-investigating trial [3].
Renal insufﬁciency may develop rapidly due to infection,
change in co-medication, ﬂuid losses or lack of ﬂuid intake.
Renal function should be estimated by calculating the
creatinine-clearance by the Cockcroft–Gault-formula [1–3].
Other formulae may overestimate renal function (Table 1) [8,9].
It has been shown recently that inappropriate use of DOAC
in patients with AF is frequent and possibly leads to adverse
events [10].
4. Conclusion
In cases of stroke, renal failure and inadequate anticoagula-
tion it is not useful to change from vitamin-K-antagonists to
‘‘low dose’’ DAOC. Diligent investigations for the cause of INR-
instability and continuation of vitamin-K-antagonist therapy
seem to be more effective and safer since there is the
opportunity of monitoring therapy and to avoid under- as
well as over-dosage.
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